Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    facet.materialart.
    facet.materialart.
    German Medical Science GMS Publishing House; Düsseldorf
    In:  54. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (gmds); 20090907-20090910; Essen; DOC09gmds038 /20090831/
    Publication Date: 2009-08-31
    Keywords: ddc: 610
    Language: German
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    facet.materialart.
    facet.materialart.
    German Medical Science GMS Publishing House; Düsseldorf
    In:  1st International Conference of the German Society of Nursing Science; 20180504-20180505; Berlin; DOC18dgpO14 /20180430/
    Publication Date: 2018-05-01
    Keywords: ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: CANCER ; human ; PROTEINS ; PATIENT ; DNA ; MECHANISM ; CONTRAST ; CYCLE ; papillomavirus ; FREQUENCY ; AGE ; MUTATION ; smoking ; COUNTRIES ; inactivation ; human papillomavirus ; TYPE-16 ; WILD-TYPE ; MUTATIONS ; HPV ; HUMAN-PAPILLOMAVIRUS ; SQUAMOUS-CELL CARCINOMA ; HEAD ; TOBACCO ; CANCER-RESEARCH ; ALCOHOL ; CONSUMPTION ; INVASIVE CERVICAL-CANCER ; NECK CANCERS ; ORAL CAVITY ; ORAL-CANCER ; DRINKING ; P53 STATUS ; SUBSET
    Abstract: TP53 mutations were analyzed in 35 human papillomavirus (HPV) type 16 DNA-positive cancers of the oral cavity and oropharynx and in 35 HPV DNA-negative cancers matched by subsite, country, sex, age, and tobacco and alcohol consumption. Wild-type TP53 was found more frequently in cancer specimens that contained HPV16 DNA than in those that did not. All 14 HPV16 DNA-positive cancers in HPV16 E6 antibody-positive patients contained wild-type TP53, compared with 50% of corresponding HPV DNA-negative cancers (matched odds ratio, infinity; 95% confidence interval, 1.4-infinity). In contrast, for HPV16 DNA-positive cancers in E6-negative patients, wild-type TP53 frequency was similar to that in corresponding HPV DNA-negative cancers (matched odds ratio, 1.0; 95% confidence interval, 0.2-5.4). TP53 inactivation is a major mechanism of HPV-related carcinogenesis in the oral cavity and oropharynx. The role of HPV in cancers also containing TP53 mutations remains to be clarified
    Type of Publication: Journal article published
    PubMed ID: 14744758
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: CANCER ; tumor ; carcinoma ; DENSITY ; SITE ; PROTEIN ; PROTEINS ; DIFFERENTIATION ; INFECTION ; MARKER ; E7 ; papillomavirus ; ASSOCIATION ; antibodies ; antibody ; PARTICLES ; IN-SITU ; WOMEN ; MARKERS ; human papillomavirus ; VIRUS-LIKE PARTICLES ; HPV ; CERVICAL-CARCINOMA ; Jun ; HEAD ; CARCINOMAS ; squamous cell carcinoma ; HUMAN-PAPILLOMAVIRUS TYPE-16 ; INFECTIONS ; NATURAL-HISTORY ; NECK CANCERS ; ABSENCE ; ELISA ; PROGRAM ; SUBSET ; ASSOCIATIONS ; TUMORIGENESIS ; INTERVAL ; CELL-CARCINOMA ; oral cancer ; HPV16 viral load ; oropharyngeal cancer ; SEXUAL-BEHAVIOR
    Abstract: A considerable subset of oropharyngeal squamous cell carcinomas (SCCs) are positive for human papillomavirus (HPV); however, delineating etiologically-associated HPV infections from SCCs with concurrent HPV infection unrelated to tumorigenesis is challenging. Viral load assessment in biopsy specimens may help facilitate such differentiation. HPV16 viral load and serologic markers were assessed among oral and oropharyngeal cases from a multinational study conducted by the International Agency for Research on Cancer (IARC). HPV16 viral load, measured semi-quantitatively by PCR-enzyme immunnassay, was dichotomized as high or low based on the median optical density value. Serologic antibodies to HPV16 virus-like particles (VLPs) and to HPV16 E6 and E7 proteins were measured by ELISA. Compared to HPV DNA-negative cases (n = 852), HPV16 DNA-positive cases with high viral load (n = 26) were significantly more likely to originate in the oropharynx (odds ratio [OR], 12.0; 95% confidence interval [CI], 5.2-27.5) and, after adjustment for tumor site (AdjOR), have antibodies against HPV16 VLPs (AdjOR, 14.6; 95% Cl, 6.0-35.6), E6 (AdjOR, 57.6; 95% CI, 21.4-155.3) and E7 (AdjOR, 25.6; 95% CI, 9.3-70.8). HPV16 DNA-positive cases with low viral load (n = 27) were more commonly oropharyngeal (OR, 2.7; 95% CI, 1.1-6.2) and seropositive for HPV16 VI Ps (AdjOR, 2.7; 95% CI, 1.1-6.9), E6 (AdjOR, 3.0; 95% CI, 0.7-14.0) and E7 (AdjOR, 3.5; 95% CI, 0.7-16.3), compared to HPV DNA-negative cases; the associations, however, were neither as strong nor as significant as the associations for high viral load. As there appears to be a strong association between HPV16 serologic markers and viral load, in the absence of data on serologic markers, HPV16 viral load may be used to help delineate the subset of HPV16 DNA-positive oral and oropharyngeal cancers that may be the consequence of HPV infection. (c) 2005 Wiley-Liss, Inc
    Type of Publication: Journal article published
    PubMed ID: 15688391
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Keywords: antibodies ; WOMEN ; cervical cancer ; human papillomavirus ; TYPE-16 ; VIRUS-LIKE PARTICLES ; E6 ; glutathione-S-transferase ; NECK-CANCER ; MALIGNANCY ; case-control study ; CARCINOMA PATIENTS ; SERUM ANTIBODIES ; E7 PROTEINS ; SEROLOGIC RESPONSE
    Abstract: Different human papillomavirus (HPV) genes are expressed during the various phases of the HPV life cycle and may elicit immune responses in the process towards malignancy. To evaluate their association with cervical cancer, antibodies against proteins from HPV16 (L1, E1, E2, E4, E6 and E7) and HPV18/31/33/35/45/52/58 (L1, E6 and E7) were measured in serum of 307 invasive cervical cancer cases and 327 controls from Algeria and India. Antibody response was evaluated using a glutathione S-transferase-based multiplex serology assay and HPV DNA detected from exfoliated cervical cells using a GP5+/6+-mediated PCR assay. Among HPV16 DNA-positive cases, seroprevalence of HPV16 antibodies ranged from 16% for HPV16 E1 to 50% for HPV16 E6 and all were significantly higher than controls. Seroprevalence of E6, E7 and L1 antibodies for HPV18 and for at least one of HPV31/33/35/45/52/58 were also higher in cases positive for DNA of the corresponding type (50% and 30% for E6 of HPV18 and HPV31/33/35/45/52/58 combined, respectively). E6 and E7 antibodies were rarely found in controls, but cross-reactivity was evident among cancer cases positive for DNA of closely phylogenetically-related HPV types. E6 or E7 antibodies against any of the eight HPV types were detected in 66.1% of all cervical cancer cases, as compared to 10.1% of controls. E6, and to a lesser extent E7, antibodies appear to be specific markers of HPV-related malignancy. However, even among cases positive for the same type of HPV DNA, approximately one-third of cervical cancer cases show no detectable immune response to either E6 or E7.
    Type of Publication: Journal article published
    PubMed ID: 24729277
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Abstract: GP5+/6+-based PCR followed by reverse line blot hybridization (GP5+/6+RLB) and multiplex type-specific PCR (E7-MPG) are two human papillomavirus (HPV) genotyping methodologies widely applied in epidemiological research. We investigated their relative analytical performance in 4,662 samples derived from five studies in Bhutan, Rwanda, and Mongolia coordinated by the International Agency for Research on Cancer (IARC). A total of 630 samples were positive by E7-MPG only (13.5%), 24 were positive by GP5+/6+RLB only (0.5%), and 1,014 were positive (21.8%) by both methods. Ratios of HPV type-specific positivity of the two tests (E7-MPG:GP5+/6+RLB ratio) were calculated among 1,668 samples that were HPV positive by one or both tests. E7-MPG:GP5+/6+RLB ratios were 〉1 for all types and highly reproducible across populations and sample types. E7-MPG:GP5+/6+RLB ratios were highest for HPV53 (7.5) and HPV68 (7.1). HPV16 (1.6) and HPV18 (1.7) had lower than average E7-MPG:GP5+/6+RLB ratios. Among E7-MPG positive infections, median mean fluorescence intensity (MFI; a semiquantitative measure of viral load) tended to be higher among samples positive for the same virus type by GP5+/6+RLB than for those negative for the same type by GP5+/6+RLB. Exceptions, however, included HPV53, -59, and -82, for which the chances of being undetected by GP5+/6+RLB appeared to be MFI independent. Furthermore, the probability of detecting an additional type by E7-MPG was higher when another type was already detected by GP5+/6+RLB, suggesting the existence of masking effects due to competition for GP5+/6+ PCR primers. In conclusion, this analysis is not an evaluation of clinical performance but may inform choices for HPV genotyping methods in epidemiological studies, when the relative merits and dangers of sensitivity versus specificity for individual types should be considered, as well as the potential to unmask nonvaccine types following HPV vaccination.
    Type of Publication: Journal article published
    PubMed ID: 27225411
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    Abstract: BACKGROUND: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. METHODS: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when 〉10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. RESULTS: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. CONCLUSIONS: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.
    Type of Publication: Journal article published
    PubMed ID: 27505134
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
    Keywords: CANCER ; CELLS ; tumor ; BLOOD ; CELL ; human ; MODEL ; MODELS ; COMMON ; RISK ; PROTEIN ; PROTEINS ; TUMORS ; PATIENT ; DNA ; MECHANISM ; E7 ; papillomavirus ; ASSOCIATION ; antibodies ; antibody ; ASSAY ; PLASMA ; etiology ; cervical cancer ; CERVICAL-CANCER ; COUNTRIES ; PCR ; cancer risk ; RISK FACTOR ; human papillomavirus ; HPV ; E6 ; HPV16 ; HUMAN-PAPILLOMAVIRUS ; SQUAMOUS-CELL CARCINOMA ; HEAD ; POLYMERASE-CHAIN-REACTION ; case-control studies ; TOBACCO ; L1 ; POLYMERASE CHAIN-REACTION ; SMOKERS ; EARLY PROTEINS ; HPV TYPE-16 ; INTERVIEW ; INVASIVE CERVICAL-CANCER ; MULTICENTER ; NECK CANCERS ; ORAL CAVITY ; RAPID DETECTION ; TONSILLAR CARCINOMAS
    Abstract: Background: Human papillomavirus (HPV), the causal agent of cervical cancer, appears to be involved in the etiology of cancer of the oral cavity and oropharynx. To investigate these associations, we conducted a multicenter case-control study of cancer of the oral cavity and oropharynx in nine countries. Methods: We recruited 1670 case patients (1415 with cancer of the oral cavity and 255 with cancer of the oropharynx) and 1732 control subjects and obtained an interview, oral exfoliated cells, and blood from all participants and fresh biopsy specimens from case patients. HPV DNA was detected by polymerase chain reaction (PCR). Antibodies against HPV16 L1, E6, and E7 proteins in plasma were detected with enzyme-linked immunosorbent assays. Multivariable models were used for case-control and case-case comparisons. Results: HPV DNA was detected in biopsy specimens of 3.9% (95% confidence interval [CI] = 2.5% to 5.3%) of 766 cancers of the oral cavity with valid PCR results and 18.3% (95% CI = 12.0% to 24.7%) of 142 cancers of the oropharynx (oropharynx and tonsil combined) with valid PCR results. HPV DNA in cancer biopsy specimens was detected less frequently among tobacco smokers and paan chewers and more frequently among subjects who reported more than one sexual partner or who practiced oral sex. HPV16 DNA was found in 94.7% of HPV DNA-positive case patients. HPV DNA in exfoliated cells was not associated with cancer risk or with HPV DNA detection in biopsy specimens. Antibodies against HPV16 L1 were associated with risk for cancers of the oral cavity (odds ratio [OR] = 1.5, 95% CI = 1.1 to 2.1) and the oropharynx (OR = 3.5, 95% CI = 2.1 to 5.9). Antibodies against HPV16 E6 or E7 were also associated with risk for cancers of the oral cavity (OR = 2.9, 95% CI = 1.7 to 4.8) and the oropharynx (OR = 9.2. 95% CI = 4.8 to 17.7). Conclusions: HPV appears to play an etiologic role in many cancers of the oropharynx and possibly a small subgroup of cancers of the oral cavity. The most common HPV type in genital cancers (HPV16) was also the most common in these tumors. The mechanism of transmission of HPV to the oral cavity warrants further investigation
    Type of Publication: Journal article published
    PubMed ID: 14652239
    Signatur Availability
    BibTip Others were also interested in ...
  • 9
    Keywords: Germany ; human ; HYBRIDIZATION ; DNA ; papillomavirus ; IDENTIFICATION ; AMPLIFICATION ; ASSAY ; WOMEN ; REPRODUCIBILITY ; CERVICAL-CANCER ; PCR ; human papillomavirus ; HIGH-RISK ; HUMAN-PAPILLOMAVIRUS ; sensitivity ; RE ; ASSAYS ; HIGH-THROUGHPUT ; TECHNOLOGY ; DNA HYBRIDIZATION ; PAP
    Abstract: Typing of human papillomaviruses (HPV) by DNA hybridization procedures, such as reverse line blot (RLB) assay, is sensitive and well validated. However, the application of these assays to high-throughput analyses is limited. Here, we describe the development of multiplex human papillomavirus genotyping (MPG), a quantitative and sensitive high-throughput procedure for the identification of multiple high- and low-risk genital HPV genotypes in a single reaction. MPG is based on the amplification of HPV DNA by a general primer PCR (GP5+/6+) and the subsequent detection of the products with type-specific oligonucleotide probes coupled to fluorescence-labeled polystyrene beads (Luminex suspension array technology). Up to 100 different HPV types can be detected simultaneously with MPG, and the method is fast and labor saving. We detected all 22 HPV types examined with high specificity and reproducibility (the median interplate coefficient of variation was below 10%). Detection limits for the different HPV types varied between 100 and 800 pg of PCR products. We compared the performance of MPG to an established RLB assay on GP5+/6+-PCR products derived from 94 clinical samples. The evaluation showed an excellent agreement (kappa = 0.922) but also indicated a higher sensitivity of MPG. In conclusion, MPG appears to be highly suitable for large-scale epidemiological studies and vaccination trials as well as for routine diagnostic purposes
    Type of Publication: Journal article published
    PubMed ID: 16455905
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    Keywords: CANCER ; CELL ; human ; screening ; POPULATION ; PROTEIN ; PROTEINS ; DNA ; INFECTION ; MARKER ; papillomavirus ; NEOPLASIA ; prevention ; HEALTH ; ASSAY ; NUMBER ; AGE ; WOMEN ; cervical cancer ; cervical intraepithelial neoplasia ; CERVICAL-CANCER ; MARKERS ; PCR ; human papillomavirus ; TYPE-16 ; FRANCE ; HIGH-RISK ; HPV ; HUMAN-PAPILLOMAVIRUS ; POPULATIONS ; UNITED-STATES ; intraepithelial neoplasia ; vaccination ; L1 ; ABNORMALITIES ; PREVALENCE ; ONCOLOGY ; RE ; GRADE ; PROTOCOL ; biomarker ; pooled analysis ; USA ; cancer research ; CANCERS ; population-based ; serology ; PUBLIC-HEALTH ; SEROPREVALENCE ; GENERAL-POPULATION ; HPV types ; HPV vaccination ; PARTNER ; HPV-16 ; HPV PREVALENCE SURVEYS ; SOUTH-KOREA
    Abstract: Data on human papillomavirus (HPV) and cervical cancer burden in Central Asia are scarce. To investigate HPV infection in Ulaanbaatar, the capital of Mongolia, we obtained cervical cell specimens from a population of 969 women ages 15 to 59 years. DNA of 44 HPV types was detected using a GP5+/6+ PCR-based assay. Seropositivity for L1 proteins of HPV 16, 18, 31, 33, 45, 52, and 58 was assessed using multiplex HPV serology. Cytologic abnormalities were detected in 127 women (13.1%), among whom 6 cervical intraepithelial neoplasia grade 3 and 2 invasive cervical cancers were diagnosed. Overall HPV DNA prevalence was 35.0%, being highest (48.5%) in women ages 〈25 years. High-risk types were detected in 24.5% of women. HPV DNA prevalence declined with age but remained 〉25% in all age groups. HPV seroprevalence was also very high (38.0%) and increased steadily from 33.2% to 48.9% in women ages 〈25 and 50 to 59 years, respectively. However, the proportion of women positive for both HPV markers of any individual HPV type was low. HPV16 was the most frequently detected type by PCR (6.1%), serology (23.0%), or both (2.1%). Lifetime number of sexual partners and induced abortions were shown to be directly associated with HPV DNA and/or seroprevalence. HPV prevalence in Ulaanbaatar was higher than that detected by similar HPV testing protocols in other populations in Asia or elsewhere and would suggest an important, yet unquantified, cervical cancer burden. Improving cervical cancer prevention, through screening and HPV vaccination, is an important public health issue for Mongolia
    Type of Publication: Journal article published
    PubMed ID: 18628425
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...